drugset / Trial / NCT00548717
Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation
Phase 2
Terminated
15 enrolled
Dana-Farber Cancer Institute
PDL BioPharma, Inc. · collabWyeth is now a wholly owned subsidiary of Pfizer · collab
Non-randomizedSingle-groupOpen-labelPrevention
Summary
This trial will test the hypothesis that the combination of sirolimus, mycophenolate mofetil, and bortezomib will be effective in preventing both acute and chronic GVHD after reduced intensity allogeneic stem cell transplantation.
Timeline
- Start
- 2007-10
- Primary completion
- 2013-09
- Completion
- 2013-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | — |
| Subject | Mycophenolate Mofetil | Small molecule | — | — |
| Subject | Sirolimus | Small molecule | — | — |